Development of potent and selective FAAH inhibitors with improved drug-like properties as potential tools to treat neuroinflammatory conditions.

The neuroprotective performance against neuroinflammation of the endocannabinoid system (ECS) can be remarkably improved by indirect stimulation mediated by the pharmacological inhibition of the key ECS catabolic enzyme fatty acid amide hydrolase (FAAH). Based on our previous works and aiming to discover new selective FAAH inhibitors , we herein reported a new series of carbamate-based FAAH inhibitors (4a - t) which showed improved drug disposition properties compared to the previously reported analogues 2a-b. The introduction of ionizable functions allowed us to obtain new FAAH inhibitors of nanomolar potency characterized by good water solubility and chemical stability at physiological pH. Interesting structure-activity relationships (SARs), deeply analyzed by molecular docking and molecular dynamic (MD) simulations, were obtained. All the newly developed inhibitors showed an excellent selectivity profile evaluated against monoacylglycerol lipase and cannabinoid receptors. The reversible mechanism of action was determined by a rapid dilution assay. Absence of toxicity was confirmed in mouse fibroblasts NIH3T3 (for compounds 4e , 4g , 4n - o , and 4s) and in human astrocytes cell line 1321N1 (for compounds 4e , 4n , and 4s). The absence of undesired cardiac effects was also confirmed for compound 4n. Selected analogues (compounds 4e , 4g , 4n , and 4s) were able to reduce oxidative stress in 1321N1 astrocytes and exhibited notable neuroprotective effects when tested in an ex vivo model of neuroinflammation. [Display omitted] • New carbamate-based FAAH inhibitors endowed with improved solubility were developed. • Compounds were characterized as potent, selective, and reversible FAAH inhibitors. • Compounds prevented ROS formation in human astrocytes stressed with TBHP. • Neuroinflammatory damage was induced in hippocampal organotypic explants. • 4e, 4g, 4n, 4s exerted neuroprotection in LPS + IFN-γ-treated hippocampal explants. [ABSTRACT FROM AUTHOR]